Press Releases

Companies press releases

Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders

– Limited to Proposal 4, Amendment to Certificate of Incorporation to Increase Authorized Common Stock – Proposals 1, 2, 3 and 5 were approved at the Annual Meeting – Scheduled to Reconvene July 23, 2020, 9:00 am Eastern Daylight Time Jun 29, 2020, 07:30 ET CRANBURY, N.J., June 29, 2020 /PRNewswire/ — Palatin Technologies, Inc. (“Palatin”) […]

Palatin Technologies Announces Adjournment of Annual Meeting of Stockholders Read More »

Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications

– Engages with Scientific, Governmental and Regulatory Agencies – Targeting Q4 2020 Initiation of an Adaptive Phase 2 Trial Jun 23, 2020, 07:30 ET CRANBURY, N.J., June 23, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide

Palatin Technologies to Develop PL8177 as a Potential Treatment for COVID-19 and Associated Lung Complications Read More »

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

– Dry Eye Disease Phase 2 Study Remains on Track – Data Anticipated in 4Q20 – $89 Million in Cash at March 31, 2020 – Teleconference and Webcast to be held on May 12, 2020 May 12, 2020, 07:30 ET CRANBURY, N.J., May 12, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical

Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights Read More »

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on May 12, 2020

May 07, 2020, 07:30 ET CRANBURY, N.J., May 7, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2020 operating results on Tuesday, May 12, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive

Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on May 12, 2020 Read More »

Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations

– Dry Eye Disease Phase 2 Study Remains on Track – Data Anticipated in 4Q20 – $89 Million in Cash at March 31, 2020 CRANBURY, N.J., April 30, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic

Palatin Technologies Provides Assessment of Impact of COVID-19 Pandemic on Business Operations Read More »

Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643

– Study Results Expected Q4 2020 Feb 19, 2020, 07:30 ET CRANBURY, N.J., Feb. 19, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today announced that it has enrolled the first patient

Palatin Technologies, Inc. Announces First Patient Enrolled in Dry Eye Disease Phase 2 Clinical Trial with PL9643 Read More »

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights

— Dry Eye Disease Phase 2 Study to Commence Q1 2020 — Data Q4 2020 — Approximately $92 Million in Cash and Cash Equivalents at December 31, 2019 — AMAG Announced Plans to Divest Vyleesi® for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) — Teleconference and Webcast to be held on February 11, 2020

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2020 Financial Results and Recent Business Highlights Read More »

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020

Feb 06, 2020, 07:30 ET CRANBURY, N.J., Feb. 6, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2020 operating results on Tuesday, February 11, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its

Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2020 Results; Teleconference and Webcast to be held on February 11, 2020 Read More »

Palatin Provides Corporate Update and 2020 Calendar Outlook

– Vyleesi® for Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) – AMAG to Divest Asset – Dry Eye Disease Phase 2 Study to Commence Q1 2020 – Data Q4 2020 – Approximately $92 Million in Cash and Cash Equivalents at December 31, 2019 Jan 21, 2020, 07:30 ET CRANBURY, N.J., Jan. 21, 2020 /PRNewswire/

Palatin Provides Corporate Update and 2020 Calendar Outlook Read More »

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update

Vyleesi™ launched nationally in September Teleconference and Webcast to be held on November 13, 2019 CRANBURY, N.J., Nov. 13, 2019 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted,

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2020 Results and Provides Corporate Update Read More »

Scroll to Top